Lalith had to make a tough choice when his mother was diagnosed with breast cancer two years ago. Along with the diagnosis, the Pune oncologist he’d met had handed him a business card that led him to a representative of the pharma major Pfizer. Since some of the prescribed medicines were not available in the hospital pharmacy, the doctor had offered a convenient solution—call the pharma representative and get the medicine delivered in just 24 hours. This seemed easy, but Lalith had to decide between buying just the medicine and a free cancer care service in the comfort of his home. Both options came with the same price tag. About Rs 12,000 ($188) per week—the retail price of the drug.

When it comes to chronic therapies, like chemotherapy, immunosuppressive therapy and dialysis that rely on specialty drugs, the expense is a major concern for Indian patients. But it is the margins in these high-value and low-volume drugs that make free at-home healthcare services possible. The markup could be as high as 1000%, but even if the profit margin is the usual 7%, the home healthcare provider, doubling up as a specialty drug distributor, can provide a few free services. Specialty drugs are priced at over Rs 10,000 ($156) per dose and may go up to a few crores for complete therapy, said a specialty drug distributor.

When these margins are combined with the potential margins in distribution, from manufacturer to distributor to end user, they can expand the market for home healthcare as well as specialty drug manufacturers, said Vivek Srivastava, the CEO of India’s oldest home healthcare company—Healthcare at Home (HCAH). “At HCAH, depending on the drug price, you could have some part of the services funded through the drug margin itself.”

Specialty therapies are growing much faster than regular pharmaceuticals. Even though there are just about 1500 brands, they account for more than one-third of the $36.7-billion Indian market today, and they are expected to make up about half of the market in next two years.

An evolving disease profile in the country—from communicable to non-communicable diseases such as hypertension, diabetes and cancers—is spurring this. Along with growing affordability, better diagnosis, specialty hospitals treating and insurers reimbursing such therapies. On the supply side, high margins, few brands and fewer prescriptions have cracked open the segment for home healthcare to double up as a specialist pharmacy to get the drug to where the patient is.

Though Lalith eventually chose to treat his 55-year-old mother in a hospital because she needed a few rounds of chemotherapy and not long-term care, he sees home healthcare as a more affordable option, especially for those who are prescribed such drugs for a long duration.

Noida-based HCAH is one of the larger players selling home healthcare with specialty drugs since it acquired the drug delivery company Health Impetus in mid-2016.

AUTHOR

Ruhi Kandhari

Ruhi writes on the impact of healthcare policies, trends in the healthcare sector and developments on the implementation of Electronic Health Records in India. She has an M. Sc. in Development Studies from the London School of Economics.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 5 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at [email protected] with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at [email protected] or follow us on Twitter.